Company-reported VYJUVEK gross margin for Q2 2026.
Source ↘Active Position · Last Updated Q2 2026
KRYS
Krystal Biotech, Inc.
HealthcareBiotechnologyGene TherapyCommercial Stage
Position Thesis
A commercial engine testing a platform thesis.
Krystal Biotech is transitioning from a development-stage biotechnology company into a profitable commercial genetic-medicine platform led by VYJUVEK, its approved treatment for dystrophic epidermolysis bullosa. VYJUVEK combines rare-disease economics, proprietary gene-delivery technology, in-house manufacturing, and a company-reported Q2 2026 gross margin of approximately 95%.
The central investment question is whether cash generated by VYJUVEK can fund additional pipeline programs without the dilution commonly associated with early-stage biotechnology companies—and whether the HSV-1 platform can ultimately support multiple approved products.
Key Fundamentals
Profitability is reaching below gross profit.
Luna1 calculation: product revenue less cost of goods sold, R&D, and SG&A, divided by product revenue.
Source ↘Approximate manually entered research ratio derived from the Q2 filing; not a company-reported metric.
Source ↘Luna1 calculation using $54.8M net income and $119.2M product revenue for Q2 2026.
Source ↘Approximate manually entered trailing research ratio; methodology should be reproduced before investment use.
Source ↘Approximate manually entered trailing research ratio; not company-reported or real-time data.
Source ↘Margin Progression
Direction matters more than a single quarter.
Gross Margin
93.46%Calculated quarterly series; latest company-reported VYJUVEK gross margin was approximately 95%.
Operating Margin
49%Calculated quarterly series based on reported financial statements.
EBITDA Margin
50.31%Approximate manually entered quarterly research series; not company-reported.
ROIC
20%Approximate manually entered trailing research series; methodology should be reproduced before use.
Progression series are manually entered Luna1 research calculations based on company filings. They are neither real-time data nor company-reported non-GAAP measures unless explicitly labeled.
VYJUVEK Commercial Performance
The cash-generating engine.
Reported · fiscal year ended December 31, 2025
Source ↘Reported · approximately +32% year over year
Source ↘Reported · approximately +24% year over year
Source ↘Reported · implies approximately 94.6% gross margin
Source ↘$119.2M revenue$6.4M COGS≈95% gross margin
VYJUVEK provides Krystal with a profitable commercial engine capable of helping finance development of the company's broader genetic-medicine pipeline.
Competitive Advantage
Why KRYS may have a moat.
Proprietary Gene-Delivery Platform
Engineered HSV-1 vectors are designed to deliver therapeutic genes directly to targeted tissues.
Redosable Gene Therapy
VYJUVEK demonstrates repeat administration, differentiating the platform from many one-time gene therapies.
Regulatory Validation
VYJUVEK approval in the United States, Europe, Japan, and the United Kingdom validates the first commercial application.
In-House Manufacturing
Two commercial-scale CGMP facilities provide control over production, quality, capacity, and unit economics.
Rare-Disease Economics
A serious rare genetic disease with limited alternatives supports attractive product economics, subject to reimbursement risk.
Platform Optionality
Programs across eye, lung, skin, and oncology indications test whether the platform can support multiple products.
KRYS Platform Flywheel
Commercial success can fund the next test.
01VYJUVEK Adoption↓
02High-Margin Revenue↓
03Free Cash Flow / Cash Generation↓
04Internally Funded R&D↓
05Additional Clinical Programs↓
06Potential New Product Approvals↓
07Larger Revenue Base↓
08Additional Cash Generation↓
09Internally Funded Innovation
Luna1 Insight
Why the margin structure matters.
A 95% gross margin alone does not make KRYS attractive. The more important signal is that high gross margins are translating into approximately 49% operating margins and approximately 50% EBITDA margins while the company continues investing in its pipeline.
The long-term question is whether one highly profitable commercial product can finance the creation of several additional successful products using the same underlying platform.
Growth Drivers
The evidence required for compounding.
- Continued VYJUVEK adoption
- International VYJUVEK expansion
- Additional reimbursement coverage
- Increased physician adoption
- Manufacturing efficiencies
- Pipeline clinical progress
- Additional indications
- New product approvals
- Operating leverage
- Internal funding of R&D
What I Am Watching
A monitoring dashboard for thesis accountability.
VYJUVEK Revenue Growth
Is product growth continuing as the revenue base becomes larger?
U.S. Product Growth
Does domestic demand remain healthy as international sales become more important?
Gross Margin
Can approximately 94%–95% gross margins remain sustainable?
Operating Margin
Does operating leverage continue while pipeline investment increases?
Pipeline Progress
Are additional HSV-1 programs progressing through clinical development?
Cash Generation
Can VYJUVEK increasingly finance R&D internally?
Competition
How are competing treatments and alternative gene-therapy technologies developing?
Regulatory Risk
What safety, manufacturing, clinical, or regulatory developments could alter the thesis?
Thesis Invalidation
What would materially weaken the case.
The investment thesis would materially weaken if VYJUVEK growth deteriorates significantly, gross margins compress structurally, safety or regulatory problems emerge, competition materially reduces the product's commercial opportunity, or the broader pipeline repeatedly fails to demonstrate that the HSV-1 platform can produce additional commercially viable therapies.
Biotechnology investments retain substantial clinical, regulatory, reimbursement, manufacturing, competition, and product-concentration risk.
Sources & Data Integrity
Reported facts remain separate from interpretation.
Fourth Quarter and Full Year 2025 Financial and Operating Results
Krystal Biotech, Inc. · February 17, 2026 · Fiscal year ended December 31, 2025
Open primary source ↗Second Quarter 2026 Financial and Operating Results
Krystal Biotech, Inc. · August 3, 2026 · Quarter ended June 30, 2026
Open primary source ↗Quarterly Report on Form 10-Q
Krystal Biotech, Inc. / U.S. SEC · August 3, 2026 · Quarter ended June 30, 2026
Open primary source ↗First Quarter 2026 Financial and Operating Results
Krystal Biotech, Inc. · May 4, 2026 · Quarter ended March 31, 2026
Open primary source ↗Quarterly Report on Form 10-Q
Krystal Biotech, Inc. / U.S. SEC · May 4, 2026 · Quarter ended March 31, 2026
Open primary source ↗This position research is for educational and informational purposes only. It reflects personal analysis and opinions and is not investment, financial, tax, or legal advice. Data may be manually entered or delayed; calculations should be independently reproduced before use.